PANTOPRAZOLE
(Panto IV, Pantoloc)Standard Prescription
pantoprazole __mg IV x 1 loading dose (__mg/kg/dose), then __mg/kg/hr continuous IV infusion x __hrs
Dosages
Children:
Acute upper GI bleed:
Gastroesophageal Reflux Disease (GERD):
<5 yrs: 0.6-1.2 mg/kg/dose PO/IV daily (max 20mg)
>=5 yrs old & <40 kg: 20 mg PO/IV daily
>=5 yrs old & >=40 kg: 40 mg PO/IV daily (If inadequate response achieved, dose may be titrated up to maximum adult dose of 80 mg/day).
Acute upper GI bleed:
5-40 kg: 2 mg/kg IV bolus once, followed by 0.2 mg/kg/hr continuous IV infusion
>40 kg: 80 mg IV once, followed by 8 mg/hr continuous IV infusion.
Maximum infusion rate is 8 mg/hr.
Maximum duration of 72 hours.
Gastroesophageal Reflux Disease (GERD):
<5 yrs: 0.6-1.2 mg/kg/dose PO/IV daily (max 20mg)
>=5 yrs old & <40 kg: 20 mg PO/IV daily
>=5 yrs old & >=40 kg: 40 mg PO/IV daily (If inadequate response achieved, dose may be titrated up to maximum adult dose of 80 mg/day).
Mechanism of Action
Proton-pump inhibitor.
Forms Supplied
Injection: 40 mg vial
Oral suspension (BCCH): 2mg/mL
Enteric coated tablets: 40 mg 20 mg (commercially available, but not stocked at BCCH)
Oral suspension (BCCH): 2mg/mL
Enteric coated tablets: 40 mg 20 mg (commercially available, but not stocked at BCCH)
Comments
A proton pump inhibitor to be used for temporary therapy of conditions which require rapid reduction in gastric acid (e.g. reflux esophagitis, gastric or duodenal ulcer) and for treatment of upper GI bleeding in children who have failed to respond to ranitidine.
Oral dosing should be administered before meals.
Not for routine stress ulcer prophylaxis.
Pediatric GI bleed dosing has been extrapolated from adult data.
May cause transient LFT elevation.
Potential for drug interactions: pantoprazole is a CYP 2C19 substrate (and 3A4 to lesser extent); effects on gastric acid excretion may interfere with absorption of drugs dependent on gastric pH.
Refer to BCCH parenteral monograph for additional administration and monitoring information.
Oral dosing should be administered before meals.
Not for routine stress ulcer prophylaxis.
Pediatric GI bleed dosing has been extrapolated from adult data.
May cause transient LFT elevation.
Potential for drug interactions: pantoprazole is a CYP 2C19 substrate (and 3A4 to lesser extent); effects on gastric acid excretion may interfere with absorption of drugs dependent on gastric pH.
Refer to BCCH parenteral monograph for additional administration and monitoring information.
References
32, 44, 434, 435, 436
Last Edited
2019-08-10 01:29:08